ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ATRA Atara Biotherapeutics Inc

0.6889
-0.0044 (-0.63%)
Last Updated: 15:59:17
Delayed by 15 minutes

Period:

Draw Mode:

Volume 692,650
Bid Price 0.6806
Ask Price 0.689
News -
Day High 0.73

Low
0.1986

52 Week Range

High
2.535

Day Low 0.6591
Company Name Stock Ticker Symbol Market Type
Atara Biotherapeutics Inc ATRA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.0044 -0.63% 0.6889 15:59:17
Open Price Low Price High Price Close Price Prev Close
0.682 0.6591 0.73 0.6933
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
3,357 692,650 $ 0.7014594 $ 485,866 - 0.1986 - 2.535
Last Trade Time Type Quantity Stock Price Currency
15:59:19 57 $ 0.6848 USD

Atara Biotherapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
70.33M 101.92M - 8.57M -276.13M -2.71 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Atara Biotherapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ATRA Message Board. Create One! See More Posts on ATRA Message Board See More Message Board Posts

Historical ATRA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.600.730.5856020.6578921,557,0310.088914.82%
1 Month0.72110.760.48430.62694471,382,668-0.0322-4.47%
3 Months0.79770.93750.48430.69247931,676,313-0.1088-13.64%
6 Months0.511.580.43230.74483922,724,5780.178935.08%
1 Year2.122.5350.19860.90623482,710,201-1.43-67.50%
3 Years13.8420.040.19864.001,755,039-13.15-95.02%
5 Years24.1928.200.19866.721,390,696-23.50-97.15%

Atara Biotherapeutics Description

Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and CAR T Programs.